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Introduction
Mesenchymal stem cells (MSCs) have been described 
as undifferentiated multipotent cells with the ability of both 
self-renewing and differentiation into a wide range of cells 
of mesenchymal lineages, such as osteoblasts, chondrocytes, 
adipocytes, (bone marrow) stromal cells, fibroblasts and ten-
dons, but also of ectodermal and endodermal types (hepato-
cytes, neural cells, lung cells, and endothelial cells) [1, 2]. 
MSCs were originally isolated from bone marrow [3] but cells 
with generally similar, although not always identical proper-
ties were found in diverse adult tissues (peripheral blood, adi-
pose tissue, trabecular bone, synovial membrane, dental pulp, 
etc.), as well as in birth-associated tissues (placenta, amnion, 
umbilical cord, and cord blood) [1, 2].
For the last two decades MSCs have gained much at-
tention because of their regenerative, reparative and an-
giogenic properties [1, 4]. Additional therapeutic poten-
tial of MSCs is related to their capacity to modulate the 
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Abstract
Mesenchymal stem cells (MScs), beside regenerative potential, possess immunomodulatory prop-
erties and their use in managing immune-mediated diseases is intensively studied. We analyzed the 
effects of MScs isolated from human adipose tissue (aT-MScs), dental pulp (DP-MScs), peripheral 
blood (Pb-MScs) and umbilical cord Wharton’s jelly (uc-MScs), on the proliferation of allogeneic 
peripheral blood mononuclear cells (PbMcs). While only aT-MScs functioned as alloantigen present-
ing cells, proliferation of PbMcs in response to a phytohemagglutinin (PHa) and alloantigens in mixed 
lymphocytes reaction (Mlr) was inhibited by all MScs in a cell concentration-dependent manner. 
conditioned medium (cM) derived from DP-MScs, Pb-MScs and uc-MScs, suppressed the baseline, 
PHa- and alloantigens-mediated proliferation of PbMc, whereas aT-MScs-derived cM inhibited Mlr, 
but failed to suppress the spontaneous and PHa-induced PbMcs proliferation. Differences between 
MSc types were observed in expression of genes related to immunomodulation, including human leu-
kocyte antigens (Hla)-a, Hla-Dr, Hla-G5, interleukin 6 (il)-6, transforming growth factor (TGF)-β, 
cyclooxygenase-2 (coX-2) and indoleamine 2,3-dioxygenase (iDo-1), under basal conditions, as well 
as in response to proinflammatory cytokines, interferon (iFn)-γ and tumor necrosis factor α (TnF)-α. 
While aT-MScs showed a positive constitutive expression of almost all tested genes that was augment-
ed in response to iFn-γ and TnF-α, only combined cytokine treatment increased Hla-a, coX2 and 
il-6 mrna expression in DP-MScs and slightly stimulated the expression of Hla-G and TGF-β in 
uc-MScs. although MScs from different tissues showed similar potential to suppress proliferation of 
PbMcs, heterogeneity in the expression of genes related to immunomodulation emphasizes the impor-
tance of investigating the role of specific molecular mechanisms in the regulation of immunomodulatory 
activity of MScs.
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immune response exerting effects on cells of both innate 
and adaptive immunity [2, 5, 6]. The immunomodulatory 
effects of MSCs include suppression of T cell prolifera-
tion, induction of regulatory T cells, suppression of B cell 
proliferation and their terminal differentiation, inhibition 
of NK cell function, as well as inhibition of differentiation 
and expression of stimulatory molecules on dendritic cells 
[2]. However, the mechanisms by which MSCs exert their 
immunomodulatory activity are only partly understood, 
although it is likely that mechanisms involving both sol-
uble factors and cell-cell contacts are involved. There is 
growing evidence that key relevant mediators of MSC-me-
diated immunomodulation include but are not limited to: 
transforming growth factor-β (TGF-β), cyclooxygenase-1 
(COX-1) and COX-2, which synthesizes prostaglandin E2 
(PGE2), indoleamine 2,3 deoxygenase (IDO), nitric oxide 
(NO), human leukocyte antigen (HLA)-G5, interleukin 6 
(IL-6), IL-10 [2, 6]. Another open issue is the relation of 
the MSCs immunomodulatory phenotype to the microen-
vironmental context, since recent data indicated that both 
MSCs behavior and function are influenced by cytokines 
and other factors secreted or accumulated in the micro-
environment, especially within the inflamed tissue [7-9]. 
MSCs of diverse origin are currently available, and each 
type has its own strength and shortcomings. Our group has 
recently isolated MSCs from four different human tissues: 
peripheral blood (PB), umbilical cord Wharton’s jelly (UC), 
adipose tissue (AT), and dental pulp (DP) from deciduous 
teeth, [10, 11, our submitted manuscript], whose common 
feature is that all are discarded after routine medical inter-
ventions and therefore are a readily available source for 
MSCs isolation. It is well documented that MSCs pheno-
type, proliferative, clonogenic and differentiation potential, 
as well as the immunomodulatory properties are influenced 
by tissue origin, donor-related health condition and age, iso-
lation technique, cultivation, propagation, and storage con-
ditions [12-14]. Therefore, comparative evaluation of MSCs 
from different sources is needed to address the existence of 
possible differences. In this study, with an aim to determine 
how tissue origin and/or proinflammatory cytokines influ-
ence the immunomodulatory phenotype, we have compared 
MSCs obtained from peripheral blood, umbilical cord Whar-
ton’s jelly, adipose tissue and deciduous teeth-dental pulp 
by evaluating their in vitro immunomodulatory capacities, 
as well as the gene expression of several molecules that are 
of importance in determination of the nature of the response 
generated by MSCs.
Material and methods 
MSCs isolation and culture 
Cell samples were obtained in accordance with the eth-
ical standards of the local ethical committee and the Dec-
laration of Helsinki, and after providing informed consent 
of study subjects. MCSs from human dental pulp of decid-
uous teeth (DP-MSCs), peripheral blood (PB-MSCs), um-
bilical cord Wharton’s jelly (UC-MSCs), as well as from 
adipose tissue (AT-MSCs), were isolated and their MSCs 
identity confirmed as previously described [10, 11]. 
After isolation, AT-MSCs, PB-MSCs, and UC-MSCs 
were further cultivated in the growth medium (GM) con-
sisting of Dulbecco’s Modified Eagle’s Medium (DMEM, 
Sigma-Aldrich) supplemented with 10% Fetal Bovine 
Serum (FBS) and Penicillin/Streptomycin (all from 
PAA, Linz, Austria), whereas DP-MSCs were cultured 
in GM with 200 μM ascorbic acid-2-phosphate (Sig-
ma-Aldrich, St. Louis, MO, USA). Cells were seeded in 
25 cm2 plastic tissue culture flasks at a concentration of 
1 × 104 cells/cm2 and incubated in a humidified atmosphere 
at 37oC and 5% CO
2
 with the medium replaced every 2-3 
days. After achieving 80-90% of confluence, MSCs were 
detached by 0.25% trypsin-EDTA solution (PAA) and re-
plated at the same cell density. All experiments were per-
formed using MSCs between passages 4 and 6.
PBMCs isolation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from buffy coats of healthy donors by density gradient 
centrifugation using Lymphoprep medium (PAA).
Conditioned media preparation
The conditioned medium (CM) derived from MSCs 
was obtained as described previously [15]. In brief, after 
reaching 80% of confluence, the cell culture medium was 
replaced by fresh GM. After additional 48 h of cultivation, 
CM-MSCs were collected. The CM-MSCs, containing fac-
tors constitutively secreted by unstimulated MSCs, were 
centrifuged for 10 min at 500 ×g and aliquots stored at 
–70oC until use.
 In vitro assays for testing MSCs modulatory 
effects on PBMCs proliferation 
One-way mixed lymphocyte reaction (MLR)
To determine if MSCs function as alloantigens present-
ing cells one-way MLR was applied. MSCs at concentra-
tions of 1 × 104 or 1 × 103 were plated in 96-well plates in 
GM and allowed to adhere at 37°C in 5% CO
2
. After over-
night incubation, MSCs were treated with Mitomycin C 
(25 μg/ml) (Applichem, Darmstadt, Germany) for 30 min at 
37°C. After washing MSCs with phosphate buffered saline 
(PBS, PAA, Linz), GM (200 ml/well) was added along with 
freshly isolated responder PBMCs (1 × 105 cells). Cultures 
of PBMCs seeded alone were used as controls. On day 2, 
cultures were pulsed with 1 × 10–5 M BrdU (Sigma-Aldrich) 
for the final 24 h. The level of proliferation, i.e. the level of 
BrdU incorporation, was measured using a modified meth-
od [16]. In brief, ethanol/HCl fixed cells were incubated 
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with mouse anti-BrdU IgG antibody (Sigma-Aldrich), and 
then with peroxidase conjugated anti-mouse IgG antibodies 
(Pierce Biotechnology, Rockford, IL, USA). After addition 
of peroxidase substrate, the level of proliferation was esti-
mated by measuring the absorbance at 450 nm. All experi-
ments were performed in triplicate. 
Mitogen-stimulated PBMCs proliferation 
To estimate the effects of MSCs on phytohaemaggluti-
nin (PHA)-stimulated proliferative response of allogeneic 
PBMCs, freshly isolated responder PBMCs (1 × 105/well), 
stimulated with 2.5 μg/ml PHA (INEP, Zemun, Serbia) 
were added in GM to MSCs cultures, previously seeded 
and treated with Mitomycin C, as described above. Cul-
tures of unstimulated and PHA-stimulated PBMCs seeded 
without MSCs were used as controls. On day 2, cultures 
were pulsed with 1 × 10-5 M BrdU for the final 24 h of cul-
ture. The level of proliferation was measured as described 
above. All experiments were performed in triplicate. 
Two-way MLR
To assess the effects of MSCs on two-way MLR (as 
a third part in MLR), PBMCs of unrelated donors (1 × 105 
cells of each) were co-cultured in GM with MSCs previous-
ly seeded and treated with Mitomycin C as described above. 
Co-cultures of responder PBMCs and allogeneic stimulator 
PBMCs without MSCs were used as controls. On day 5, 
cultures were pulsed with 1 × 10-5 M BrdU for the final 24 h. 
The level of proliferation was measured as described above. 
All experiments were performed in triplicate. 
Conditioned media experiments
The effects of MSCs-derived soluble products were as-
sessed in both PHA-stimulated PBMC proliferation and the 
one- and two-way MLR. Briefly, 1 × 105 responder PBMCs, 
incubated in the presence or absence of 2.5 μg/ml PHA, or 
with 1 × 105 PBMCs of unrelated donors for the MLR, were 
exposed to GM supplemented with 20% CM of each MSCs 
type for 3 or 6 days and cultured in triplicate at 37°C, 5% of 
CO
2
 before the MTT assay was carried out. The experiments 
were performed at least three times and cultures without CM 
were used as controls. The PBMC proliferation rate was de-
termined by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphen-
yltetrazolium bromide) assay. Three hours after adding 0.5 
mg/ml MTT (Sigma-Aldrich), the formazan crystals were 
dissolved in 10% SDS with 0.01 N HCl and absorbance read 
at 540 nm. 
 Reverse transcription-polymerase chain reaction  
(RT-PCR)
For gene expression analyses, MSCs treated or not 
with recombinant human IFN-γ (50 ng/ml) and/or TNF-α 
(20 ng/ml) (all from R&D Systems, Minneapolis, MN, 
USA) for 7 days were used. In a separate experiment, sub-
confluent MSCs were co-cultured for 2 days, with 1 × 106 
allogeneic unstimulated or PHA-stimulated PBMCs. Cells 
grown only in GM were used as controls. Total RNA from 
MSCs was extracted using TRIzol (Invitrogen, Carlsbad, 
California, USA) and complementary DNA generated by 
the RevertAid TM Hminus First Strand cDNA Synthesis 
Kit (Fermentas, Life Science, Glen Burnie, MD, USA) us-
ing oligo (dT) as a primer. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a control for the 
amount of cDNA present in each sample. The primers sets 
were all purchased from Invitrogen, Carlsbad, CA (Table 
1). PCR bands were quantified by densitometry using the 
ImageMaster TotalLab v1.11 software (Amersham Phar-
macia Biotech, Uppsala, Sweden). The expression level of 
each gene was normalized to GAPDH and set as 1 for con-
trol culture. The relative expression in stimulated MSCs 
was expressed as “fold change” compared to the control.
Primer Forward sequence 5’-3’ Reverse sequence 5’-3’ Annealing 
temperature 
(°C)
Cycles Product size 
(bp)
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 52 35 452
HLA-A GACGACACGCAGTTCGTGC CATGTCCGCCGCGGTCCAA 49 31 331
HLA-G5 GGAAGAGGAGACACGGAACA CCTTTTCAATCTGAGCTCTTCTTT 47 40 771
HLA-DRα CGAGTTCTCTATCTGAATCCTG GTTCTGCTGCATTGCTTTTGC 52 33 644
IL-6 ATGAACTCCTTCTCCACAAG AGAGCCCTCAGGCTGGACTG 53 35 626
COX2 CCTTCCTCCTGTGCCTGATG CTGGCCCTCGCTTATGATCT 59 35 203
IDO-1 ATCACCATGGCATATGTGTGGG GTGAAACACTTGAAGGGCTTTCTC 51 33 390
TGF-β GGGACTATCCACCTGCAAGA CCTCCTTGGCGTAGTAGTCG 50 33 239
Table 1. 
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Statistical analyses
The results are presented as the mean ± standard de-
viation (SD). The statistical significance of differences 
between two groups was determined by the two-tailed 
Student’s t-test. Differences with P-values of < 0.05 were 
considered significant. 
Results
 Immunomodulatory properties of different MSC 
populations
First, we analyzed if MSCs can act as alloantigens 
presenting cells. Different concentrations of MSCs inac-
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Fig. 1A–C. Influence of AT-MSCs, DP-MSCs, PB-MSCs, and UC-MSCs on spontaneous (A), mitogen- (B) or alloantigen-induced (C) PB-
MCs proliferation. A) The alloantigen presenting function of AT-MSCs, DP-MSCs, PB-MSCs, and UC-MSCs. Allogeneic PBMCs (1 × 105) 
were co-cultured for three days in GM with Mitomycin C-pretreated MSCs at 1 : 100 and 1 : 10 MSCs/PBMCs ratios. B) The modulatory 
effect of AT-MSCs, DP-MSCs, PB-MSCs, and UC-MSCs on PHA-stimulated proliferation of PBMCs. Allogeneic PBMCs (1 × 105) stim-
ulated with 2.5 μg/ml PHA were co-cultured for three days in GM with Mitomycin C-pretreated MSCs at 1 : 100 and 1 : 10 MSCs/PBMCs 
ratios. C) The AT-MSCs, DP-MSCs, PB-MSCs, and UC-MSCs as third part modulators of two-way MLR. PBMCs (1 × 105) of two unrelated 
donors were cultivated for six days in GM with Mitomycin C-pretreated MSCs at 1 : 100 and 1 : 10 MSCs/PBMCs ratios. The proliferation 
of PBMCs was determined by BrdU incorporation. The allogeneic PBMCs cultured without MSCs were used as controls and the prolifera-
tion value in control cultures were expressed as equal to 1. The data are mean ± SD of three to six independent experiments performed in 
triplicate. Results are presented as a relative proliferation index where the level of proliferation of PBMCs in allogeneic MLR was set at 1 
* p < 0.05, ** p < 0.01 and *** p < 0.001 compared to the corresponding controls
allogeneic PBMCs before the resulting PBMCs prolifera-
tion was assessed. As shown in Fig. 1A, only AT-MSCs 
stimulated the proliferation of allogeneic PBMCs, and just 
at the 1 : 10 AT-MSCs to PBMCs ratio. On the other hand, 
PB-MSCs did not exert any effect, while DP-MSCs and 
UC-MSCs even suppressed the proliferation of PBMCs in 
a MSC concentration-dependent manner. 
Next, we evaluated the effect of MSCs on the mi-
togen-mediated lymphocyte proliferation and obtained 
results demonstrated that all tested MSCs inhibited the 
proliferation of PBMCs in response to PHA treatment in 
a MSC concentration-dependent manner (Fig. 1B). The 
UC-MSCs significantly inhibited the PBMC proliferation 
at both cell concentrations tested, i.e. at MSCs/PBMCs ra-
tio of 1 : 10 and 1 : 100, whereas AT-MSCs, DP-MSCs, 
A B
C
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and PB-MSCs showed marked suppression only when 
there was MSCs 1 × 104/well, i.e. 1 : 10 MSCs/PBMCs 
ratio. 
Further on, we investigated the influence of different 
MSCs on MLR triggered by allogeneic antigens and results 
shown in Fig. 1C confirmed that all MSC populations sup-
pressed the proliferation of PBMCs induced by allogeneic 
PBMCs, with AT-MSCs exhibiting the most significant in-
hibitory effect. Although all cell populations inhibited the 
MLR in a MSC concentration-dependent manner, the ef-
fects varied regarding the cell concentration, i.e. the MSC/
effector cell ratio, at which higher levels of suppression 
were observed. Namely, for the AT-MSCs and UC-MSCs, 
significant inhibition was detected with both MSC con-
centrations used, for DP-MSCs a more prominent effect 
was seen at the 1 : 100 MSC/effector cell ratio, where-
as PB-MSCs exhibited significant effect when there was 
a 1 : 10 MSC/effector cell ratio.
 To assess the effects of MSC-secreted bioactive mol-
ecules, we next investigated the capacity of their condi-
tioned medium (CM) to affect either the spontaneous or 
mitogen-induced proliferation of allogeneic PBMCs, as 
well as the MLR reaction. As shown in Fig. 2, CM de-
rived from DP-MSCs, PB-MSCs and UC-MSCs, consid-
erably suppressed the proliferation of allogeneic PBMC 
(Fig. 2A), the PHA-mediated proliferation (Fig. 2B) and 
the MLR (Fig. 2C). On the other hand, although the MLR 
was effectively inhibited (Fig. 2C), the AT-MSCs-derived 
CM failed to suppress the baseline proliferation capacity 
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Fig. 2. Effects of CM derived from AT-MSCs, DP-MSCs, PB-MSCs, and UC-MSCs on spontaneous (A), mitogen- (B) or 
alloantigen-induced (C) PBMCs proliferation. Allogeneic responder PBMCs (1 × 105), incubated in the absence of mitogen 
A) or presence of 2.5 μg/ml PHA B), or with PBMCs (1 × 105) of unrelated donors C), were exposed to GM supplemented 
with 20% CM of each MSCs type for 3 or 6 days. PBMCs maintained in GM represented controls. Cell proliferation was 
determined by MTT test. The data are mean of four to seven independent experiments performed in triplicate. Results are 
presented as a relative proliferation index where the baseline proliferation level of control PBMCs cultures was set at 1 
* p < 0.05, ** p < 0.01 and *** p < 0.001 compared to the corresponding controls
A B
C
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responses (Fig. 2B), most probably due to marked indi-
vidual variations within the effects detected for different 
PBMCs donors.
 Analysis of immunomodulatory related genes 
expression in different MSC populations
The expression of genes related to MSCs immuno-
modulatory functions was next investigated and compared. 
Beside their constitutive expression profiles in the MSC 
populations studied, transcript levels of HLA-A, HLA-G, 
HLA-DR, IL-6, TGF-β, COX2 and IDO-1 were also an-
alyzed following the IFN-γ and TNF-α stimulation, since 
the proinflammatory microenvironment, including these 
two cytokines, has been implicated in the initiation of the 
MSCs immunomodulatory phenotype (Fig. 3). 
Regarding the members of the HLA family, the con-
stitutive expression of both classical HLA-A class I and 
non-classical HLA-G5 class I molecules, as well as the 
HLA-DR, was not detected in PB-MSCs, UC-MSCs and 
DP-MSCs, while low levels of HLA-A and HLA-DR 
mRNA were detected only for AT-MSCs. As for the basal 
gene expression of the molecules related to the paracrine 
effects of MSCs, a low level of IDO-1 transcript was deter-
mined only in AT-MSCs, whereas AT-MSCs, PB-MSCs 
and UC-MSCs displayed similar low expression levels 
for the TGF-β mRNA. Concerning the IL-6 and COX2 
marked expression of their transcript levels was demon-
strated for the AT-MSCS and DP-MSCs.
Further on, the gene expression in MSCs was deter-
mined after cytokine treatment and as shown in Fig. 3, the 
effects of the two proinflammatory cytokines used, dif-
fered between the MSC populations. In AT-MSCs, in re-
sponse to IFN-γ and TNF-α, either alone or combined, an 
augmented expression of almost all tested genes (HLA-A, 
HLA-DR, HLA-G, COX2, IDO-1, IL-6 and TGF-β) was 
determined. It is worth mentioning that IFN-γ and TNF-α 
Fig. 3. Constitutive and IFN-γ and/or TNF-α modulated gene expression of molecules related to immunomodulatory 
capacity in AT-MSCs, DP-MSCs, PB-MSCs, and UC-MSCs. MSCs were cultivated in GM with or without IFN-γ 
(50 ng/ml) and/or TNF-α (20 ng/ml) for 7 days. Gels from the representative experiment are presented. GAPDH was used 










 0  IFN + TNF IFN  TFN
 1 4.9 16.5 30.0
 1 2.0 12.0 5.7
 1 1.1 1.6 0
 1 0.8 0.4 2.5
 1 4.2 1.60 4.0
 1 0.8 1.3 2.3
 1 0.9 1.5 2.0
DP-MSC
 0  IFN + TNF IFN  TFN
 1 15.5 1.3 1.1
 
 1 1 1.7 1.4
 1 1.6 0.5 1
 
 1 1.8 1.6 1.1
PB-MSC






 1 0.9 0.8 0.7
UC-MSC
 0  IFN + TNF IFN  TFN
 
 
 1 3.2 2.7 1.5
 
 
 1 2.3 1.3 0.8
Central European Journal of Immunology 2013; 38(4) 427
Immunomodulatory capacity of human mesenchymal stem cells isolated from adipose tissue, dental pulp, peripheral blood and 
umbilical cord Wharton’s jelly
combined stimulation did not induce synergistic upregu-
lation of the tested genes. As for the DP-MSCs, the op-
posite effect was observed, since only the combined cy-
tokine pre-treatment increased the expression of HLA-A, 
HLA-G5, COX2 and IL-6. Regarding the PB-MSCs, 
pre-treatment with these two proinflammatory cytokines 
did not alter the mRNA expression of tested molecules, 
while in response to IFN-γ and TNF-α, a slightly stimu-
lated expression of HLA-G molecule and TGF-β was de-
termined in UC-MSCs. 
Discussion 
In our laboratory MSCs from adipose tissue, dental 
pulp of deciduous teeth, peripheral blood and Wharton’s 
jelly of umbilical cord were recently isolated and charac-
terized exhibiting typical MSC morphology, clonogenic 
potential, immunophenotype and multipotent capacity to 
differentiate along mesenchymal lineages (osteogenic, 
chondrogenic, adipogenic and myogenic) in vitro [10, 11]. 
It is known that MSCs isolated from different tissues have 
similar but not identical capacity to modulate immune 
response. There are studies in which immunomodulatory 
properties of MSCs isolated from different tissues were 
directly compared [17-20], but because of a great variety in 
applied experimental procedures it is still difficult to know 
which of these MSCs are the most suitable for a specif-
ic therapeutic approach. Our results showed that types of 
MSCs analyzed in this study differed in both, capacity to 
modulate proliferation of allogeneic PBMCs and, constitu-
tive or induced (by proinflammatory cytokines) expression 
of several genes related to the immunomodulatory proper-
ties of MSCs. 
We showed, as expected, that in the direct cell culture 
all MSCs types inhibited the proliferation of PBMCs in 
response to both the mitogen (PHA) and alloantigens. We 
performed our assays at relatively high MSCs to PBMCs 
ratios of 1 : 10 and 1 : 100, which according to previous 
data are “more physiological” than lower MSCs to re-
sponder cell ratio [21]. The inhibition of PBMCs prolifer-
ation obtained was cell-concentration dependent. Namely, 
for PHA-stimulated PBMCs proliferation, all MSCs types 
induced a more pronounced inhibitory effect at lower 
1 : 10 MSCs to PBMCs ratio. Besides, for alloantigen-in-
duced PBMCs proliferation more prominent inhibition was 
induced by AT-MSCs and UC-MSCs at both cell concen-
trations used, whereas DP-MSCs and PB-MSCs exerted 
an inhibitory effect only at 1 : 100 or 1 : 10 MSCs/PBMCs 
ratios, respectively. Data that cell ratio determines wheth-
er MSCs would act as stimulators or inhibitors have been 
published previously [9, 22]. 
Regarding the allostimulatory function, DP-MSCs, 
PB-MCSs, and UC-MSCs did not provoke alloreactiv-
ity in vitro, but in contrast to them, AT-MSCs stimu-
lated proliferation of allogeneic PBMCs, but only at the 
1 : 10 AT-MSCs to PBMCs ratio. Other authors have also 
demonstrated that MSCs are able to provoke alloimmune 
response both in vitro [23] and in vivo [24]. Furthermore, 
the allostimulatory function previously demonstrated for 
bone marrow MSCs was shown to be dependent on cell-to-
cell contact, but not on the soluble factor(s), as it was not 
abolished when metabolic activity of MSCs was prevented 
by pretreatment with cross-linking fixatives [23]. In addi-
tion, the allostimulatory function of MSCs demonstrated in 
that study was related to the constitutive membrane expres-
sion of HLA-DR molecule. However, the AT-MSCs used 
in our study constitutively express HLA-DR mRNA but 
not the membrane HLA-DR protein (our submitted man-
uscript), being in accordance with reports that HLA-DR 
molecules are habitually not expressed as surface markers 
unless MSCs are stimulated/primed within the inflamma-
tory milieu [25, 26]. Nevertheless, to better understand the 
mode of action of AT-MSCs on PBMCs proliferation, fur-
ther studies should be performed to determine if increased 
AT-MSCs-stimulated proliferation of PBMCs was the 
result of stimulated proliferation of regulatory T cells as 
previously shown [27]. 
Immunomodulatory activity of MSCs could be mediat-
ed by direct cell contact or by secreted molecules [18, 28, 
29] and which mechanisms predominate is highly depen-
dent on the applied experimental design. There are several 
articles demonstrating opposite effects of constitutively 
secreted molecules by MSCs on proliferation of alloge-
neic lymphocytes [2, 15, 17]. Our results showed that CM 
of confluent, unstimulated MSCs also differentially mod-
ulate proliferation of PBMCs. Namely, CM derived from 
DP-MSCs, PB-MSCs, and UC-MSCs considerably sup-
pressed the proliferation of allogeneic PBMC, as well as 
the proliferation of PBMCs in response to the mitogen and 
alloantigens. On the other hand, AT-MSCs’ culture super-
natant exerted different immunomodulatory properties, as 
it effectively inhibited MLR, but had no effect on baseline 
proliferation capacity and PHA-stimulated proliferation 
of PBMCs. The observed inhibitory effect of CM derived 
from DP-MSCs, PB-MSCs, and UC-MSCs on prolifera-
tion of PBMCs could be a consequence of induced apop-
tosis or cell cycle arrest. However, further studies should 
address this issue in more detail. On the other hand, pre-
vious data evidenced the capacity of bone marrow MSCs 
to support survival of unstimulated T cells [30]. Whether 
the same is the case for AT-MSCs whose CM did not exert 
an inhibitory effect on PBMCs proliferation remains to be 
determined. 
Further on, in the present study we showed that MSCs 
isolated from different sources in our laboratory signifi-
cantly differed in the constitutive expression of several 
genes related to MSCs immunomodulatory functions. All 
tested MSC types shared a common negative expression 
of HLA-G5, while the constitutive gene expression of 
HLA-A and HLA-DR was evidenced only for AT-MSCs. 
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Our results showing that all tested MSCs did not express 
constitutively one of the main mediators of immunosup-
pression, HLA-G5, were unexpected, since previously 
published data evidenced the expression of HLA-G5 in 
MSCs from different tissue sources [31]. As for the mol-
ecules related to the paracrine effects of MSCs, a marked 
expression of IL-6 and COX2 mRNA was demonstrated 
for the AT-MSCs and DP-MSCs, a low level of IDO-1 
transcript only in AT-MSCs, whereas AT-MSCs, PB-
MSCs and UC-MSCs displayed similar low expression 
levels for the TGF-β mRNA. 
Since the proinflammatory microenvironment has been 
involved in the initiation of the immunomodulatory phe-
notype, we also analyzed the gene expression in MSCs 
following stimulation with proinflammatory cytokines, 
such as IFN-γ and TNF-α. Our results showed that the ef-
fects of these proinflammatory cytokines differed between 
the MSC types. Namely, in response to IFN-γ and TNF-α, 
either alone or combined, an increased expression of al-
most all tested genes (HLA-A, HLA-DR, HLA-G, COX2, 
IDO-1, IL-6 and TGF-β) was determined in AT-MSCs. 
However, we observed that IFN-γ and TNF-α combined 
stimulation did not induce synergistic upregulation of the 
tested genes in these cells, while for the DP-MSCs the op-
posite effect was demonstrated as only the combined cy-
tokine pre-treatment increased the expression of HLA-A, 
COX2 and IL-6. On the other hand, IFN-γ and TNF-α did 
not alter the expression of tested genes in PB-MSCs, while 
slightly stimulated the expression of HLA-G and TGF-β 
in UC-MSCs. 
Previous studies demonstrated that IFN-γ and TNF-α 
not only differentially regulate the expression of various 
immunomodulatory factors by human MSCs, but also that 
these pro-inflammatory cytokines differentially affect the 
immune properties of different tissue-derived MSCs [32, 
33]. According to our knowledge, a suppressive effect of 
the combination of TNF-α and IFN-γ on the expression of 
genes related to immunomodulatory capacity of MSCs has 
not been shown. Moreover, it was shown that the combina-
tion of these cytokines increased the expression of IDO-1 
in bone-marrow, adipose tissue, cord blood and Wharton’s 
jelly MSCs [34].
Although we and other research groups showed that 
MSCs isolated from different tissues varied in their capac-
ity to modulate in vitro proliferative response of allogeneic 
PBMCs, we cannot conclude that their different function 
and gene-expression profiles are entirely a consequence 
of their tissue origin. Indeed, in any tissue MSCs are not 
necessary phenotypically and functionally homogenous 
[35-37], and applied isolation procedures could result in 
isolation of different MSCs subpopulation even from the 
same tissues. Also, influence of donors’ age and health 
on properties of isolated MSCs cannot be neglected [38], 
as well as impact of further cultivation and propagation 
[12, 13]. Besides, differences in immunomodulatory ca-
pacity of MSCs even from the same tissue origin could be 
a consequence of an experimental design applied in vitro, 
including the reciprocal influence on MSCs by the PBMC 
used in the assays, since their membrane or secreted mol-
ecules were also shown to affect the MSCs function [6]. 
Even more, it has been recently shown that MSCs can 
sense local microenvironment signals and in accordance 
with them promote optimal immune response, which can 
be either stimulatory or inhibitory depending on current 
specific needs of an organism [6]. 
In general, our results confirmed that MSCs from 
different tissues have immunomodulatory properties, as 
proliferation of PBMCs in response to mitogen or allo-
antigens was suppressed by all tested MSCs in cell-con-
centration-dependent manner. In addition, data obtained 
using CM MSCs indicated the involvement of soluble 
molecules produced by MSCs in inhibition of PBMCs 
proliferation. However, variations in the suppression level 
of allogeneic PBMCs proliferation observed for different 
types of MSCs, as well as marked heterogeneity in the ex-
pression of genes related to immunomodulation, empha-
size the importance of investigating the intrinsic molecular 
mechanisms underlying MSCs immunomodulatory activity 
in order to provide insights for defining an optimal MSC 
candidate for cell-base immunotherapy. 
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